Investment Thesis
Guardant Health, Inc. (GH), a company providing cancer screening tests, has seen its top-line rising exponentially in recent quarters amid growing margins. The share price has surged ~17% higher since the recent upward guidance to 2019 outlook. The growing volumes and prices continue to power the revenue momentum. The concurrent improvement in margins softens the liquidity constraints amid an ongoing trial for early cancer detection. The late-stage data improve early-stage test accuracy positioning the company ahead of the curve. An FDA approval expected next year could boost market access for late-stage